NASDAQ:JAZZ Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis $229.55 +0.78 (+0.34%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$236.86 +7.32 (+3.19%) As of 08:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Jazz Pharmaceuticals Stock (NASDAQ:JAZZ) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Jazz Pharmaceuticals alerts:Sign Up Key Stats Today's Range$227.64▼$231.4350-Day Range$178.55▼$232.3352-Week Range$105.00▼$235.00Volume685,870 shsAverage Volume959,616 shsMarket Capitalization$14.40 billionP/E RatioN/ADividend YieldN/APrice Target$238.00Consensus RatingModerate Buy Company Overview Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders. Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy. In oncology, its marketed medicines include Vyxeos® (daunorubicin and cytarabine liposome) for newly diagnosed therapy-related acute myeloid leukemia, Zepzelca® (lurbinectedin) for small cell lung cancer, and Defitelio® (defibrotide) for hepatic veno-occlusive disease. Through the acquisition of GW Pharmaceuticals in 2021, Jazz added Epidiolex® (cannabidiol) to its portfolio for rare epilepsy syndromes. Founded in 2003 and headquartered in Dublin, Ireland, Jazz maintains research, development and commercial operations across North America, Europe and Asia-Pacific. The company expanded its capabilities through a series of strategic mergers and acquisitions, including the 2011 combination with Azur Pharma and the 2021 purchase of GW Pharmaceuticals, strengthening its position in both neurology and oncology. Under the leadership of President and Chief Executive Officer Bruce C. Cozadd, Jazz Pharmaceuticals continues to advance its clinical pipeline with investigational candidates in sleep disorders, neurodevelopmental conditions and various cancer indications. The company emphasizes global collaboration and strategic partnerships to accelerate the delivery of novel therapies to patients worldwide.AI Generated. May Contain Errors. Read More Jazz Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreJAZZ MarketRank™: Jazz Pharmaceuticals scored higher than 53% of companies evaluated by MarketBeat, and ranked 508th out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingModerate Buy Consensus RatingJazz Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 15 buy ratings, 1 hold rating, and 1 sell rating.Upside/DownsideThe consensus price target for Jazz Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageJazz Pharmaceuticals has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Jazz Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth6.99% Earnings GrowthEarnings for Jazz Pharmaceuticals are expected to grow by 6.99% in the coming year, from $20.75 to $22.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jazz Pharmaceuticals is -11,471.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jazz Pharmaceuticals is -11,471.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioJazz Pharmaceuticals has a PEG Ratio of 0.41. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioJazz Pharmaceuticals has a P/B Ratio of 3.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Jazz Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.48% of the float of Jazz Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverJazz Pharmaceuticals has a short interest ratio ("days to cover") of 5.33.Change versus previous monthShort interest in Jazz Pharmaceuticals has recently decreased by 2.86%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJazz Pharmaceuticals does not currently pay a dividend.Dividend GrowthJazz Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.83 News SentimentJazz Pharmaceuticals has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Jazz Pharmaceuticals this week, compared to 7 articles on an average week.Search Interest6 people have searched for JAZZ on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows5 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Jazz Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,180,486.00 in company stock.Percentage Held by Insiders4.30% of the stock of Jazz Pharmaceuticals is held by insiders.Percentage Held by Institutions89.14% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Jazz Pharmaceuticals' insider trading history. Receive JAZZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JAZZ Stock News HeadlinesJazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 18 at 2:59 AM | americanbankingnews.comJazz Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst QuestionsMay 15, 2026 | finance.yahoo.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.May 19 at 1:00 AM | Banyan Hill Publishing (Ad)Some Investors May Be Willing To Look Past Jazz Pharmaceuticals' (NASDAQ:JAZZ) Soft EarningsMay 14, 2026 | finance.yahoo.comJazz Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 12, 2026 | prnewswire.comUBS Remains a Hold on Jazz Pharmaceuticals (JAZZ)May 10, 2026 | theglobeandmail.comJazz Pharmaceuticals Signals Confidence After Record QuarterMay 9, 2026 | theglobeandmail.comRaymond James Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)May 9, 2026 | theglobeandmail.comSee More Headlines JAZZ Stock Analysis - Frequently Asked Questions How have JAZZ shares performed this year? Jazz Pharmaceuticals' stock was trading at $170.00 at the beginning of 2026. Since then, JAZZ stock has increased by 35.0% and is now trading at $229.55. How were Jazz Pharmaceuticals' earnings last quarter? Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) posted its quarterly earnings results on Tuesday, March, 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $1.07 billion during the quarter. Jazz Pharmaceuticals had a trailing twelve-month return on equity of 14.56% and a net margin of 0.66%. Does Jazz Pharmaceuticals have any subsidiaries? Jazz Pharmaceuticals subsidiaries include Cavion. Who are Jazz Pharmaceuticals' major shareholders? Jazz Pharmaceuticals' top institutional investors include Dimensional Fund Advisors LP (3.02%), Bank of New York Mellon Corp (2.68%), Swedbank AB (1.58%) and Renaissance Technologies LLC (1.31%). Insiders that own company stock include Bruce C Cozadd, Seamus Mulligan, Robert Iannone, Neena M Patil, Mary Elizabeth Henderson, Philip L Johnson, Heather Ann Mcsharry, Rick E Winningham, Norbert G Riedel, Mark Douglas Smith and Patricia Carr. View institutional ownership trends. How do I buy shares of Jazz Pharmaceuticals? Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Jazz Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Jazz Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings3/31/2026Today5/19/2026RBC Capital Markets Global Healthcare Conference 20265/19/20267th Annual Oncology Innovation Summit: Insights for ASCO & EHA5/27/2026Jefferies Global Healthcare Conference 20266/03/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 JAZZ's financial health is in the Green zone, according to TradeSmith. JAZZ has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceuticals Current SymbolNASDAQ:JAZZ CIK1232524 Webwww.jazzpharma.com Phone(531) 634-7800Fax353-1634-7850Employees2,890Year Founded2003Price Target and Rating Average Price Target for Jazz Pharmaceuticals$230.56 High Price Target$275.00 Low Price Target$152.00 Potential Upside/Downside+0.4%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)($0.02) Trailing P/E RatioN/A Forward P/E Ratio11.06 P/E Growth0.41Net Income-$356.15 million Net Margins0.66% Pretax Margin-4.93% Return on Equity14.56% Return on Assets5.25% Debt Debt-to-Equity Ratio0.95 Current Ratio2.04 Quick Ratio1.85 Sales & Book Value Annual Sales$4.44 billion Price / Sales3.24 Cash Flow$16.31 per share Price / Cash Flow14.07 Book Value$71.07 per share Price / Book3.23Miscellaneous Outstanding Shares62,743,000Free Float60,045,000Market Cap$14.40 billion OptionableOptionable Beta0.27 Social Links The 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:JAZZ) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredIs the SpaceX IPO “Rigged?”The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jazz Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Jazz Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
